C4's Partnership with Roche, Gilead Options Kymera degrader, and Astellas Licenses Dyno Capsid
Plus the initial dosing of Enanta and Avencell's Clinical Trials
Triveni's New Digs, 99 Coolidge's Tenant Bonanza, and Remix's FDA Fast Track Designation
Plus Addgenes' new partnership, and Neumora and Acrivon's cash flow updates
Watertown Bio Journal Club: How Targeted is Targeted Protein Degradation?
Evaluating the potential impact of off-target degradation of KT-474
Kymera and Psithera's Funding Haul
A Multi-Million dollar public offering, the developing race for a dupilumab alternative, business awards, and more.
Cultivarium's Next Steps
Stratus Therapeutics winding down, Consider the ALS TDI for Giving Tuesday, and more
Labshares Expanding to Watertown
Neumora's Wegovy alternative, Dyno announces manufacturing pact, and more
Watertown Bio Journal Club: How Many Ways Can You Break a Protein?
Talking about proteases, PROTACs, and molecular glues. Plus new methods for mass spec tagging, viral inhibitors, and more.